Helping cancer survivors restoring their natural breast with resorbable implants...
Helping cancer survivors restoring their natural breast with resorbable implants inducing self tissue regeneration
Tensive was founded in 2012 to address the challenge of developing better biomaterials for regenerative medicine. We developed a bio absorbable scaffold based on highly biocompatible polyurethaneester. Our patented scaffolds prov...
ver más
¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video
Información proyecto REGENERA
Duración del proyecto: 43 meses
Fecha Inicio: 2018-05-25
Fecha Fin: 2021-12-31
Líder del proyecto
TENSIVE SRL
No se ha especificado una descripción o un objeto social para esta compañía.
TRL
4-5
Presupuesto del proyecto
3M€
Fecha límite de participación
Sin fecha límite de participación.
Descripción del proyecto
Tensive was founded in 2012 to address the challenge of developing better biomaterials for regenerative medicine. We developed a bio absorbable scaffold based on highly biocompatible polyurethaneester. Our patented scaffolds provide a synthetic micro-vascular network that enables adipocytes colonization in vivo. This unique design leads to vascularization, fat integration and volume maintaining after implantation. Based on these unique properties, we will bring to the market REGENERA, an innovative mammary prosthesis that is degraded over time and replaced by the patient´s fat. Silicone implants, the most currently used breast tissue modifications, have important risks and need replacement every 10-15 years. Fat grafting, the best alternative nowadays, has been linked to carcinogenic risks and does not promote vascularization (leading to necrosis) with multiple interventions needed for large reconstructions. REGENERA, which only requires one surgical intervention, will meet the need to develop biomaterials able to promote new blood vessels formation that perpetuate the reconstructed tissue. REGENERA will have a significant impact on various levels: (i) Healthcare system: it will save the cost of additional surgeries (more than €241M yearly in the EU), helping to the sustainability of the Healthcare system. (ii) breast cancer patients: it will offer a solution to lumpectomy patients, for whom there are no good solutions yet; a better alternative for mastectomy and breast augmentation patients; a permanent solution by a single surgery for all patients, improving their quality of life. (iii) company: it will increase Tensive’s revenues (cumulative profit of €257M with a ROI of 19.37 by 2025) (iv) society: it will highly benefit 230,000 women needing reconstructive surgery after breast cancer, together with the 1.35M women undergoing breast augmentation for personal reasons